Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02019758 |
|
Recruitment Status :
Completed
First Posted : December 24, 2013
Results First Posted : April 26, 2019
Last Update Posted : April 27, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose: To determine whether oral viscous budesonide (OVB) or fluticasone metered dose inhaler (MDI) most effectively treats EoE by improving histologic findings and symptoms, which medication provides a more durable treatment response, and whether biomarkers can predict treatment response.
Participants: A total of up to 200 16-80 year old patients with a new diagnosis of eosinophilic esophagitis (EoE) who are referred for upper endoscopy will be consented with a target of 122 randomized.
Procedures: This will be a prospective, randomized, double-blind, double-dummy, clinical trial comparing OVB to fluticasone MDI for treatment of EoE. This overall study design will generate data for all three Aims
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Eosinophilic Esophagitis | Drug: Oral Viscous Budesonide Drug: Fluticasone MDI Drug: Placebo slurry Drug: Placebo inhaler | Phase 4 |
This will be a prospective, randomized, double-blind, double-dummy, clinical trial comparing oral viscous budesonide (OVB) to fluticasone metered dose inhaler (MDI) for treatment of EoE. A total of 122 subjects aged 16-80 years old will be randomized in a 1:1 fashion to one of two active treatment arms: OVB + placebo inhaler or fluticasone MDI + placebo slurry.
In the first arm, subjects will be treated with OVB at a dose of 1 mg twice daily, and they will also be instructed to use a placebo inhaler identical to the fluticasone MDI, with instructions to swallow 4 puffs twice daily. The OVB is a slurry equivalent to what is used clinically: 1 mg/4 mL aqueous budesonide mixed with 10 g of sucralose. Rather than asking the subjects to mix the slurry on their own and risk inconsistent formulations, the University of North Carolina (UNC) investigational drug pharmacy (IDP) will provide pre-mixed OVB to all patients. The IDP will also provide placebo inhalers to all patients. The dose for OVB has been chosen because it is the most commonly studied dose, including one prior study led by this Principal Investigator, so we can accurately estimate response rates.
In the second arm, subjects will be treated with fluticasone MDI at a dose of 880 mcg twice daily (4 puffs of a 220 mcg inhaler twice daily), and they will also be instructed to take 4 mL twice daily of a placebo slurry of sucralose identical in consistency and taste to the OVB. The UNC investigational drug pharmacy (IDP) will provide the fluticasone MDIs and pre-mixed placebo slurries to all patients. The dose for fluticasone MDI has been chosen because this is the most commonly used dose in adolescents and adults with EoE, so effect estimates are also available.
For both arms, the slurry will be administered first, the MDI will be administered 15 minutes later, and patients will take nothing by mouth for an additional 30 minutes.
Subjects will receive 8 weeks of treatment and will then be monitored for up to 52 weeks for recurrence of symptoms.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 129 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis |
| Actual Study Start Date : | January 1, 2015 |
| Actual Primary Completion Date : | May 2018 |
| Actual Study Completion Date : | April 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Oral Viscous Budesonide (OVB)
Subjects will be treated with OVB at a dose of 1 mg twice daily, and they will also be instructed to use a placebo inhaler identical to the fluticasone MDI, with instructions to swallow 4 puffs twice daily.
|
Drug: Oral Viscous Budesonide
Oral Viscous Budesonide - 1 mg/4 mL, 4 mL of slurry twice daily
Other Name: Pulmicort Drug: Placebo inhaler Placebo inhaler - 4 puffs twice daily
Other Name: Placebo |
|
Active Comparator: Active Fluticasone MDI
Subjects will be treated with fluticasone MDI at a dose of 880 mcg twice daily (4 puffs of a 220 mcg inhaler twice daily), and they will also be instructed to take 4 mL twice daily of a placebo slurry of sucralose identical in consistency and taste to the OVB.
|
Drug: Fluticasone MDI
Fluticasone multi-dose inhaler - 4 puffs twice daily (880 mcg, twice daily)
Other Name: Flovent Drug: Placebo slurry Slurry of sucralose - 4 mL twice daily
Other Name: Sucralose |
- Post-Treatment Maximum Eosinophil Count (Aim 1) [ Time Frame: 8 weeks ]To determine whether viscous budesonide is more effective than fluticasone MDI for improving post-treatment maximum esophageal eosinophil counts (measured in eosinophils per high powered field (eos/hpf)) in patients with eosinophilic esophagitis (EoE). The mean post-treatment maximum eosinophil count will be compared between the OVB and MDI groups using a two-sample t-test.
- Post-treatment Dysphagia Score (Aim 1) [ Time Frame: 8 weeks ]To determine whether viscous budesonide is more effective than fluticasone MDI for improving dysphagia (measured by the Daily Symptoms Questionnaire (DSQ)) in patients with EoE. The mean DSQ scores will be compared between the OVB and MDI groups using a two-sample t-test. The DSQ is a dysphagia severity score which ranges from 0-84, with higher numbers indicating more severe symptoms.
- Post-treatment Endoscopic Severity (Aim 1) [ Time Frame: 8 weeks ]Endoscopic severity will be quantified using the EoE Endoscopic Reference Score (EREFS) and compared between the two treatment arms. EREFS is a validated endoscopic severity score of key EoE endoscopic features (exudates, rings, edema, furrows, and strictures), and ranges from 0-9 with higher scores indicating higher endoscopic severity.
- Percentage of Participants With Histologic Response of <15 Eos/Hpf [ Time Frame: 8 weeks ]Percentage with histologic response, with response defined as <15 eos/hpf, will be compared between groups
- Post-treatment Symptom Severity (Aim 1) [ Time Frame: 8 weeks ]Post-treatment symptoms severity will be assessed with the EoE Symptom Activity Index (EEsAI), a validated dysphagia severity measure. The EEsAI ranges from 0-100, with higher scores indicating more severe symptoms; symptom remission is defined by a score <20.
- Post-treatment Medication Compliance (Aim 1) [ Time Frame: 8 weeks ]Medication compliance as measured by the percentage of medication appropriately used in each arm. For the slurry, this percentage is calculated after measuring the residual volume. For the inhaler, this percentage is calculated after measured using the residual weight.
- Median Number of Days Until Symptom Recurrence (Aim 2) [ Time Frame: Symptom recurrence or 1 year after completing the initial 8 week treatment ]To test whether OVB results in less symptomatic recurrence than fluticasone MDI, the median number of days until symptom occurrence will be quantified between treatment end (week 8) and recurrent symptoms or study end (week 60) as the time of interest. Hazard ratio will be calculated using Cox proportional modeling.
- Number of Subjects With Histologic Recurrence, Defined as ≥15 Eosinophils Per High-power Field, at Follow-up Endoscopy. [ Time Frame: Symptom recurrence or 1 year after completing the initial 8 week treatment ]To test whether OVB results in less histologic recurrence than fluticasone MDI, the number of subjects with ≥15 eosinophils per high-power field at follow-up endoscopy in each group will be compared using chi-square.
- Mean Endoscopic Severity Score at Recurrence (Aim 2) [ Time Frame: Symptom recurrence or 1 year after completing the initial 8 week treatment ]Measurement of endoscopic severity, using the EoE Endoscopic Reference Score (EREFS) measure, at the time of recurrence. EREFS is a validated endoscopic severity score of key EoE endoscopic features (exudates, rings, edema, furrows, and strictures), and ranges from 0-9 with higher scores indicating higher endoscopic severity.
- Mean Peak Eosinophil Count (Aim 2) [ Time Frame: Symptom recurrence or 1 year after completing the initial 8 week treatment ]This will assess the mean peak level of esophageal eosinophilia on biopsy (measured in peak eosinophil count - eos/hpf) at the time of recurrence
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 16 Years to 80 Years (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion criteria are as follows:
- Age: 16 - 80 years
- Subject is having a clinically indicated endoscopy for suspicious EoE and has been on twice daily (BID) proton pump inhibitor (PPI) for at least 8 weeks OR New diagnosis of EoE as per consensus guidelines. Cases must have symptoms of dysphagia, persistent esophageal eosinophilia (≥ 15 eosinophils in at least one high-power field) after 8 weeks of treatment with a twice daily proton-pump inhibitor, and other competing causes of esophageal eosinophilia excluded.
Exclusion criteria are as follows:
- Medical instability that precludes safely performing upper endoscopy
- Ongoing or recent symptoms of intestinal bleeding (throwing up blood, passing blood in the stool)
- Concomitant eosinophilic gastroenteritis
- Esophageal narrowing or stricturing that will not allow a standard 9 mm upper endoscopy scope to pass
- Cancer in the esophagus, stomach, or intestine
- Previous esophageal surgery
- Esophageal varices (dilated blood vessels in the esophagus)
- Current use of blood thinners like Plavix or Coumadin that are not stopped prior to endoscopy procedures
- Any corticosteroid exposure within the 4 weeks prior to their baseline endoscopic exam. Exclusionary corticosteroid exposure is defined as any swallowed topical steroids for EoE or systemic steroids for any condition within the four weeks prior to the baseline endoscopy. Corticosteroids used for asthma or intranasal corticosteroids are not an exclusion and are allowable.
- Pregnancy
- Inability to read or understand English
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02019758
| United States, North Carolina | |
| University of North Carolina, Chapel Hill | |
| Chapel Hill, North Carolina, United States, 27599 | |
| Principal Investigator: | Evan S Dellon, MD, MPH | University of North Carolina, Chapel Hill |
Documents provided by University of North Carolina, Chapel Hill:
| Responsible Party: | University of North Carolina, Chapel Hill |
| ClinicalTrials.gov Identifier: | NCT02019758 |
| Other Study ID Numbers: |
13-4047 R01DK101856 ( U.S. NIH Grant/Contract ) |
| First Posted: | December 24, 2013 Key Record Dates |
| Results First Posted: | April 26, 2019 |
| Last Update Posted: | April 27, 2020 |
| Last Verified: | May 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Esophagitis Eosinophilic Esophagitis Esophageal Diseases Gastrointestinal Diseases Digestive System Diseases Gastroenteritis Eosinophilia Leukocyte Disorders Hematologic Diseases Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Fluticasone |
Budesonide Anti-Inflammatory Agents Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Dermatologic Agents Anti-Allergic Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists |